p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma

Pancreas

Volumn 13, Issue 3, 1996, Pages 241-246

  Raedle, Jochen ^a   Oremek, Gerhard ^a   Welker, Mathias ^a   Roth, W Kurt ^b   Caspary, Wolfgang F ^a   Zeuzem, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Acute pancreatitis; Anti p53 autoantibodies; Chronic pancreatitis; Pancreatic carcinoma; Tumor screening

Indexed keywords

AUTOANTIBODY; CA 19-9 ANTIGEN; PROTEIN ANTIBODY; PROTEIN P53; TUMOR MARKER;

ACCURACY; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PANCREATITIS; PRIORITY JOURNAL;

EID: 0029822806     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199610000-00005     Document Type: Article

References (32)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
4. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
5. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
6. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
7. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
8. Legros Y, Meyer A, Ory K, Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 1994;9: 3689-94.
9. Schlichtholz B, Trédaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
10. Volkmann M, Müller M, Hofmann WJ, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 1993;18:559-65.
11. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
12. Casey G, Yamanaka Y, Friess H, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
13. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-98.
14. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-11.
15. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
16. Köhler H, Lankisch PG. Acute pancreatitis and hyperamylasaemia in pancreatic carcinoma. Pancreas 1987;2:117-9.
17. Lin A, Feller ER. Pancreatic carcinoma as a cause of unexplained pancreatitis: report of ten cases. Ann Intern Med 1990;113:166-7.
18. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995;109:247-51.
19. Fernandez E, La Vecchia C, Porta M, Negri E, d'Avanzo B, Boyle P. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995;11:185-9.
20. Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. Gastroenterology 1985;88:1973-95.
21. Benamouzig R, Buffet C, Fourre C, Ink O, Moati F, Etienne JP. Serum levels of carbohydrate antigenic determinant (CA 19.9) in obstructive jaundice. Dig Dis Sci 1989;34:1640-2.
22. Gullo L. CA 19-9: the Italian experience. Pancreas 1994;9: 717-9.
23. Satake K, Takeuchi T, Homma T, Ozaki H. CA 19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994;9:703-6.
24. Satake K, Takeuchi T. Comparison of CA 19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994;9:720-4.
25. Schmiegel W. Tumor markers in pancreatic cancer - current concepts. Hepatogastroenterology 1989;36:446-9.
26. Hermanek P, Sobin LH, eds. TNM classification of malignant tumours. New York: Springer-Verlag, 1992.
27. Marxsen J, Schmiegel W, Röder C, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-4.
28. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995;36: 455-8.
29. Raedle J, Roth WK, Oremek G, Caspary WF, Zeuzem S. α-Fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci 1995;40:2587-94.
30. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994;145:1291-5.
31. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
32. Zhang SY, Ruggeri B, Agarwal P, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.